MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced the receipt of a grant from the UK Research and Innovation (UKRI) to support first-in-man trials of its pivotal IL-6-driven hyperinflammation programme.

“For the past few months, we have been focussing exclusively on our IL-6 removal product in order to respond to the pandemic. IL-6 is an “inflammatory cytokine”, a signalling molecule produced by your immune system in response to an infection like COVID-19. In severe cases, an overproduction of IL-6 causes the immune system to overreact, which can cause organ damage and death. The removal of IL-6 from critical patients can prevent this overreaction and thereby improve outcomes,” said Dr Cristina Blanco-Andujar, Chief Technology Officer at MediSieve. “We look forward to advance this new technology that could contribute to the global effort to end the COVID-19 pandemic.”

The COVID programme builds upon MediSieve’s existing IL-6 product, which was developed to help patients suffering from sepsis, cytokine release syndrome, and other hyperinflation conditions. Earlier this year the company has been awarded a COVID-19 Continuity Grant from Innovate UK, which provided extra funding worth £222k for their previously awarded Biomedical Catalyst Grant.

About MediSieve

MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

MEDIA CONTACT:

Alina Kagermazova
alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham
george@medisieve.co.uk

Sort by: Newest First Oldest First Most Popular Most unliked